atul arora - Academia.edu (original) (raw)

Papers by atul arora

Research Square (Research Square), Mar 15, 2024

To analyze the evolution of uveitis diagnosis over a 10-year period, emphasizing the change in et... more To analyze the evolution of uveitis diagnosis over a 10-year period, emphasizing the change in etiological diagnosis, and the factors associated with recurrences. Design: Retrospective chart review Methods A total of 15000 patients with uveitis presented to our tertiary care institute in North India between 1992 and 2023. Of these,123 patients completed 10-year follow-up and were included in the study. The data of patients was collected on an o ine purpose-built uveitis registry portal:Ocular Autoimmune Systemic In ammatory and Infectious Study(OASIS). Results The study included 123 patients (48.78% males; mean age:29.11 ± 15.22 years).The most common anatomical and etiological diagnosis at presentation were anterior (49/123,34.96%) and idiopathic(59/123,47.97%) uveitis respectively.At the end of 10 years, anterior uveitis remained the most common anatomical diagnosis(43/123,39.83%) while the most common etiological diagnosis was immune-mediated uveitis(50/123,40.65%). An etiological diagnosis could be established in 50.85% (30/59) of patients initially labelled as idiopathic.Tuberculous uveitis(39/44,88.63%) and Juvenile Idiopathic Arthritis associated uveitis (16/49,32.65%) were the commonest infectious and immunemediated etiologies at the 10-year follow-up. Ninety-six(80.67%) patients experienced multiple episodes of ocular in ammation with a mean recurrences rate of 0.386 ± 0.24 recurrences/year. Anterior uveitis(p = 0.01), the change in etiological diagnosis after the rst year(p = 0.03), positive HLA-B27 at baseline(p = 0.04), and the diagnosis of a systemic disease prior to onset of uveitis were associated with higher recurrences rates(p = 0.03). Conclusion Over 10-year of follow up, half of the uveitis diagnosis evolved from idiopathic to speci c infectious or immune-mediated etiologies.Our results indicate that patients with a high recurrence rate may bene t from re-evaluation to nd the de nitive cause of uveitis.

Joint Bone Spine, Jun 1, 2023

Retina-the Journal of Retinal and Vitreous Diseases, Aug 1, 2023

We read with interest the recent paper by Chhablani et al 1 reporting the outcome of recalcitrant... more We read with interest the recent paper by Chhablani et al 1 reporting the outcome of recalcitrant and naive eyes with diabetic macular edema (DME) treated with intravitreal dexamethasone implant (Ozurdex) injection. Although the study is indeed interesting, there are certain points we wish to highlight. First, as systemic hypertension is a risk factor for the development of both diabetic retinopathy and DME, and hyperlipidemia increases the risk of leakage and exudative deposits in the macula, 2 blood pressure and lipid profile should have been recorded at baseline and at subsequent visits to assess whether improvement in macular edema was as a result of strict systemic control or as a result of the implant itself. Second, according to the authors, 7 eyes had proliferative diabetic retinopathy (PDR), and 26 had lasered PDR. These 26 eyes had undergone panretinal photocoagulation, minimum of 4 months before the first Ozurdex implant was administered. What about the remaining seven eyes that had PDR? Were they lasered during the follow-up period after implant insertion? If panretinal photocoagulation was performed during the follow-up, it could acutely worsen the DME and affect the visual outcomes. 3 Third, authors need to rectify the discrepancy in the values; in the manuscript, it is mentioned that 'mean treatment-free interval among naive eyes and previously treated eyes was 10.53 ± 7.8 and 6.5 ± 4.5 months, respectively', whereas in Table 1, the mean treatment-free interval in previously treated eyes has been written as 6.17 ± 3.3 months.

Survey of Ophthalmology, Mar 1, 2023

Indian Journal of Ophthalmology, 2022

Retina-the Journal of Retinal and Vitreous Diseases, Aug 23, 2022

Ocular Immunology and Inflammation, Oct 28, 2022

Retina-the Journal of Retinal and Vitreous Diseases, Jan 23, 2021

Ocular Immunology and Inflammation

Saudi Journal of Ophthalmology, Jan 10, 2023

Retina-the Journal of Retinal and Vitreous Diseases, Nov 28, 2022

Ocular Immunology and Inflammation

Indian journal of ophthalmology, 2022

Indian Journal of Ophthalmology

Indian Journal of Ophthalmology

Journal of Medical Mycology

Indian Journal of Ophthalmology

RETINAL Cases & Brief Reports

Research Square (Research Square), Mar 15, 2024

To analyze the evolution of uveitis diagnosis over a 10-year period, emphasizing the change in et... more To analyze the evolution of uveitis diagnosis over a 10-year period, emphasizing the change in etiological diagnosis, and the factors associated with recurrences. Design: Retrospective chart review Methods A total of 15000 patients with uveitis presented to our tertiary care institute in North India between 1992 and 2023. Of these,123 patients completed 10-year follow-up and were included in the study. The data of patients was collected on an o ine purpose-built uveitis registry portal:Ocular Autoimmune Systemic In ammatory and Infectious Study(OASIS). Results The study included 123 patients (48.78% males; mean age:29.11 ± 15.22 years).The most common anatomical and etiological diagnosis at presentation were anterior (49/123,34.96%) and idiopathic(59/123,47.97%) uveitis respectively.At the end of 10 years, anterior uveitis remained the most common anatomical diagnosis(43/123,39.83%) while the most common etiological diagnosis was immune-mediated uveitis(50/123,40.65%). An etiological diagnosis could be established in 50.85% (30/59) of patients initially labelled as idiopathic.Tuberculous uveitis(39/44,88.63%) and Juvenile Idiopathic Arthritis associated uveitis (16/49,32.65%) were the commonest infectious and immunemediated etiologies at the 10-year follow-up. Ninety-six(80.67%) patients experienced multiple episodes of ocular in ammation with a mean recurrences rate of 0.386 ± 0.24 recurrences/year. Anterior uveitis(p = 0.01), the change in etiological diagnosis after the rst year(p = 0.03), positive HLA-B27 at baseline(p = 0.04), and the diagnosis of a systemic disease prior to onset of uveitis were associated with higher recurrences rates(p = 0.03). Conclusion Over 10-year of follow up, half of the uveitis diagnosis evolved from idiopathic to speci c infectious or immune-mediated etiologies.Our results indicate that patients with a high recurrence rate may bene t from re-evaluation to nd the de nitive cause of uveitis.

Joint Bone Spine, Jun 1, 2023

Retina-the Journal of Retinal and Vitreous Diseases, Aug 1, 2023

We read with interest the recent paper by Chhablani et al 1 reporting the outcome of recalcitrant... more We read with interest the recent paper by Chhablani et al 1 reporting the outcome of recalcitrant and naive eyes with diabetic macular edema (DME) treated with intravitreal dexamethasone implant (Ozurdex) injection. Although the study is indeed interesting, there are certain points we wish to highlight. First, as systemic hypertension is a risk factor for the development of both diabetic retinopathy and DME, and hyperlipidemia increases the risk of leakage and exudative deposits in the macula, 2 blood pressure and lipid profile should have been recorded at baseline and at subsequent visits to assess whether improvement in macular edema was as a result of strict systemic control or as a result of the implant itself. Second, according to the authors, 7 eyes had proliferative diabetic retinopathy (PDR), and 26 had lasered PDR. These 26 eyes had undergone panretinal photocoagulation, minimum of 4 months before the first Ozurdex implant was administered. What about the remaining seven eyes that had PDR? Were they lasered during the follow-up period after implant insertion? If panretinal photocoagulation was performed during the follow-up, it could acutely worsen the DME and affect the visual outcomes. 3 Third, authors need to rectify the discrepancy in the values; in the manuscript, it is mentioned that 'mean treatment-free interval among naive eyes and previously treated eyes was 10.53 ± 7.8 and 6.5 ± 4.5 months, respectively', whereas in Table 1, the mean treatment-free interval in previously treated eyes has been written as 6.17 ± 3.3 months.

Survey of Ophthalmology, Mar 1, 2023

Indian Journal of Ophthalmology, 2022

Retina-the Journal of Retinal and Vitreous Diseases, Aug 23, 2022

Ocular Immunology and Inflammation, Oct 28, 2022

Retina-the Journal of Retinal and Vitreous Diseases, Jan 23, 2021

Ocular Immunology and Inflammation

Saudi Journal of Ophthalmology, Jan 10, 2023

Retina-the Journal of Retinal and Vitreous Diseases, Nov 28, 2022

Ocular Immunology and Inflammation

Indian journal of ophthalmology, 2022

Indian Journal of Ophthalmology

Indian Journal of Ophthalmology

Journal of Medical Mycology

Indian Journal of Ophthalmology

RETINAL Cases & Brief Reports